| pubmed-article:19195454 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19195454 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19195454 | lifeskim:mentions | umls-concept:C1435444 | lld:lifeskim |
| pubmed-article:19195454 | lifeskim:mentions | umls-concept:C1425020 | lld:lifeskim |
| pubmed-article:19195454 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:19195454 | pubmed:dateCreated | 2009-2-6 | lld:pubmed |
| pubmed-article:19195454 | pubmed:abstractText | The ARTEMIS study compared the efficacy of darunavir/ritonavir at once-daily doses of 800/100 mg versus once- or twice-daily doses of lopinavir/ritonavir, together with 300 mg of tenofovir and 200 mg of emtricitabine, both in once-daily doses, in treatment-naive patients. The results at 48 weeks show that darunavir/ritonavir is not inferior to lopinavir/ritonavir; the increase in CD4 count observed with both regimens was similar. Darunavir/ritonavir was superior to lopinavir/ritonavir in patients with high viral loads (>100,000 copies/mL). The use of darunavir/ritonavir was associated with a lower proportion of grades 2-4 adverse effects, especially gastrointestinal effects such as diarrhea and with a lower frequency of lipidic adverse effects, such as increased triglyceride and total cholesterol levels. Once-daily darunavir/ritonavir may be an option in first-line antiretroviral therapy, with the added advantage of a reduced dose of ritonavir and high efficacy in patients with elevated viral loads. | lld:pubmed |
| pubmed-article:19195454 | pubmed:language | spa | lld:pubmed |
| pubmed-article:19195454 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19195454 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19195454 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19195454 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19195454 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19195454 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19195454 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19195454 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19195454 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19195454 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19195454 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:19195454 | pubmed:issn | 0213-005X | lld:pubmed |
| pubmed-article:19195454 | pubmed:author | pubmed-author:EstradaVicent... | lld:pubmed |
| pubmed-article:19195454 | pubmed:author | pubmed-author:FusterMónicaM | lld:pubmed |
| pubmed-article:19195454 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19195454 | pubmed:volume | 26 Suppl 10 | lld:pubmed |
| pubmed-article:19195454 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19195454 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19195454 | pubmed:pagination | 10-3 | lld:pubmed |
| pubmed-article:19195454 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:meshHeading | pubmed-meshheading:19195454... | lld:pubmed |
| pubmed-article:19195454 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:19195454 | pubmed:articleTitle | [Darunavir in treatment-naïve patients. The ARTEMIS study]. | lld:pubmed |
| pubmed-article:19195454 | pubmed:affiliation | Medicina Interna/Enfermedades Infecciosas. Hospital Clínico San Carlos. Madrid. España. vestradap@medynet.com | lld:pubmed |
| pubmed-article:19195454 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19195454 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:19195454 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:19195454 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19195454 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:19195454 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
